Trade and market developmentTrade and market development

News

TeraXion's High-Speed Photonics Components Division is Acquired by Ciena

News - TeraXion and Ciena announced today that they have entered into a definitive agreement where Ciena will acquire TeraXion's High-Speed Photonics Components (HSPC) assets for approximately $CA 46.6 million (USD $32 million) in cash.

TSO3 Establishes Medical Industry’s First-Ever Claims for Duodenoscope Terminal Sterilization

News - TSO3, an innovator in sterilization technology for medical devices in healthcare settings, has added to its label claims for the STERIZONE® VP4 sterilizer in Canada that validates the ability to sterilize a specific duodenoscope.

Opsens Receives Orders Worth $1.2 Million for its FFR Products from Japan

News - Opsens Inc. is pleased to announce receipt of orders worth over $1.2 millionfor its products to measure Fractional Flow Reserve ("FFR") from the Japanese market. Opsens' FFR products are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease. The orders placed by Opsens' Japanese distributor, a player in interventional cardiology at the head of a well-organized distribution network, more than double Opsens' FFR revenues from fiscal year 2015.

B-TEMIA initiates pivotal clinical trial to support commercial launch of Keeogo™ in the U.S.

News - B-TEMIA Inc., the market leader in human augmentation, today announced that it has initiated a multi-centre pivotal clinical trial, aimed at demonstrating the superior clinical benefits and safety for home use of its powered assistive Demoskeleton™ technology, called Keeogo™, for patients suffering from reduced mobility due to their medical conditions. Led by Principal Investigator, Dr. Chris A. McGibbon, PhD, from the University of New Brunswick's, Faculty of Kinesiology and Institute of Biomedical Engineering, the study is expected to generate the required data to support the submission of a 510(k) pre-market notification to the U.S. Food and Drug Administration in 2016, a prerequisite to start commercialization in the United States.

OPSENS granted approval to sell OptoWire II in Europe

News - Opsens Inc. is pleased to announce it has been granted CE marking for the OptoWire II, the improved version of its pressure guidewire (OptoWire I) developed to measure Fractional Flow Reserve ("FFR") in patients with coronary artery disease. CE marking allows Opsens to sell OptoWire II in Europe, the world's second largest market.

Opsens announces first use of its FFR products in the United States

News - Opsens Inc. is pleased to announce that the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve ("FFR"), were used for the first time in the United States by Dr. Morton J. Kern and Dr. Arnold Seto at the University of California, Irvine and VA Long Beach, California. Opsens' FFR products are designed for the diagnostic of the functional severity of coronary stenoses and to guide their treatment.

B-Temia and Sagem Sign a Partnership Agreement in the Field of Exoskeletons for Industrial and Military Applications

News - Canadian company B-Temia, Inc. and French company Sagem (Safran) announced the signature of a technological and business development agreement concerning a new-generation of exoskeletons for industrial and military applications. Exoskeletons are bio-mechanical and electronic structures worn on the body to assist and enhance people's movements, or to restore mobility.

Opsens receives Health Canada approval to commercialize its FFR products

News - Opsens Inc. announced it has received Health Canada's approval to commercialize the OptoWire and OptoMonitor, its products developed to measure Fractional Flow Reserve ("FFR"). FFR is used to optimize the diagnosis and guide the treatment of patients with coronary heart disease.

TSO3 creates U.S. entity - Plans to open U.S. facility

News - TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings, announced the formation of a wholly owned subsidiary: TSO3 Corporation, structured under the laws of the State of Delaware, and located in the State of South Carolina, USA. The new entity is being created to meet the demands of US customers for product, service and education.

Opsens gets clearance to sell FFR products in the United States

News - Opsens Inc. today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the OptoWire and OptoMonitor, its products developed to measure Fractional Flow Reserve (“FFR”). This measure is used to optimize the diagnostic and guide the treatment of patients with coronary heart disease. This clearance gives Opsens permission to sell its FFR products in the United States, the world’s largest FFR market.

Contacts

MargaritaMottaForeign Market Development

More details

GuillaumeBlanchardTechnology Entrepreneurship

More details

Newsletter

Subscribe to our newsletter for interesting news and information.

Print this page